基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 生化试剂 激动剂抑制剂 维立诺雷 维立诺雷
  • aladdin 阿拉丁 V414145 维立诺雷 1352792-74-5 98%

aladdin 阿拉丁 V414145 维立诺雷 1352792-74-5 98%

Verinurad (RDEA3170)
1352792-74-5
799.90 5mg 起订
978.90 25mg 起订
1173.90 100mg 起订
上海 更新日期:2025-05-16

上海阿拉丁生化科技股份有限公司

VIP3年
联系人:阿拉丁客服
电话:400-6206333拨打
手机:13167063860 拨打
邮箱:anhua.mao@aladdin-e.com

产品详情:

中文名称:
维立诺雷
英文名称:
Verinurad (RDEA3170)
CAS号:
1352792-74-5
品牌:
阿拉丁
产地:
上海
保存条件:
-20°C储存
纯度规格:
Moligand™, ≥98%
产品类别:
小分子和化合物库 配体家族
分子式:
C20H16N2O2S
分子量:
348.42
运输条件:
超低温运输
产品规格:
25mg、5mg、100mg
货号:
V414145
是否进口:

中文名:维立诺雷

英文名:Verinurad (RDEA3170)

纯度:Moligand™,≥98%

货号:V414145

Cas号:1352792-74-5

存储温度:-20°C储存

运输条件:超低温运输

产品介绍:

Information

Verinurad (RDEA3170) Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter with an IC50 of 25 nM for inhibiting transport activity of human URAT1. It inhibits the related URAT1 homologs OAT4 and OAT1 with approximately 200-fold lower affinity compared to URAT1 with IC50 values of 5.9 µM and 4.6 µM, respectively.


Targets

URAT1 transporter (Cell-free assay) 25 nM


In vitro

Verinurad inhibited the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC50 of 25 nM. Verinurad inhibited the related URAT1 homologs OAT4 and OAT1 with approximately 200-fold lower affinity compared to URAT1 with IC50 values of 5.9 μM and 4.6 μM, respectively. Human URAT1 (IC50=0.025 μM) has a 1,640-fold higher affinity for verinurad compared to rat URAT1(IC50 = 41 μM). Verinurad has a high potency for human URAT1, and residues 35, 365 and 481 all contribute to verinurad affinity. Human URAT1 carrying a chimeric point mutation at position 365, in which human Phe-365 is replaced by rat Tyr-365 (human URAT1-F365Y or h-F365Y) has an IC50 of 4.0 μM, a significant 160-fold lower affinity relative to human URAT1. Meanwhile, rat URAT1 carrying the opposite point mutation (rat URAT1-Y365F or r-Y365F), had an IC50 of 2.9 μM, a significant 14-fold higher affinity compared to rat URAT1.


In vivo

In human, absorption of a single dose is rapid, and exposure (Cmax and AUC) increases with dose up to the maximum dose tested. Cmax is at 0.5-0.75 hours post dose in the fasted state, and is slightly delayed to 1.25 hours post dose in the fed state. The t1/2 is approximately 10-15 hours across doses. Verinurad was well tolerated at the doses studied. In the systemic circulation, verinurad appeared to be a high clearance drug (CL/F ranged ~30-50 L/h) with extensive extravascular distribution. Renal excretion of verinurad is limited to only ~2%–3% in the urine, suggesting that the majority of verinurad is likely cleared in the liver via biotransformation to metabolites.


Cell Research(from reference)

Cell lines:HEK-293T cells 

Concentrations:0.1 nM-1 mM 

Incubation Time:5 min 


查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/V414145.html


CAS No.:1352792-74-5 ; C72401 ; SB19753 ; CCG-268013

公司简介

上海阿拉丁生化科技股份有限公司是A股上市公司((股票代码:688179),专注于科研试剂的研发、生产和销售,已陆续建立多个工厂和研发中心。作为领军企业,阿拉丁始终坚持质量第一,连续13年被评为“最受欢迎试剂品牌”。 阿拉丁目前常备库存试剂产品品种超过7万种,SKU总数超过46万,产品线涵盖了化学试剂、生化试剂、药靶配体、蛋白质和抗体等多个领域,是国内少数化学试剂到生物试剂全面发展的国产试剂品牌,产品同步发布在我们国内外电商平台。

成立日期 (17年)
注册资本 14130.676万人民币
员工人数 500人以上
年营业额 ¥ 1亿以上
经营模式 工厂,试剂
主营行业 生物化工,化学试剂

维立诺雷相关厂家报价 更多

  • 雷诺嗪
  • 雷诺嗪
  • 武汉维斯尔曼生物工程有限公司 VIP
  • 2026-02-03
  • ¥3000
  • 雷诺嗪
  • 雷诺嗪
  • 沧州恩科医药科技有限公司 VIP
  • 2026-02-02
  • ¥999
  • 雷诺嗪
  • 雷诺嗪
  • 湖北威德利化学科技有限公司 VIP
  • 2026-02-03
  • ¥1500
  • Verinurad
  • Verinurad
  • 武汉铼辉生物科技有限公司
  • 2024-04-16
  • ¥3000
内容声明
拨打电话 立即询价